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A personalized medicine, a recent trend of clinical pharmacology, makes possible the individual approach to the
choice of the drugs and their dosage. According to the results of a study of the activity of different biomarkers,
particularly the isoenzymes of the cytochrome P-450, they provide the efficiency and safety of the pharmacotherapy.
The activity of the isoenzymes of the cytochrome P-450 determines an individual pharmacological response and
depends on many factors, including genetic ones. The biomarkers of the activity of the isoenzymes of the
cytochrome P-450 should be tested in the clinical practice settings using the simple and cheap methods, one of
the most available is an immunofluorescent assay. The skilled staff and the centers of personalized medicine are
necessary for this approach.
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Personalized pharmacotherapy: traditional approach or
new perspectives
There is a long-standing opinion that pharmacotherapy
should be personalized, but physicians did not have the
method of choice of drugs and their dosage. The neces-
sity of the individual approach to the choice of the drugs
is determined by the efficiency of pharmacotherapy (not
more than 60% (WHO)) and the increased frequency of
the adverse drug reactions (up to fatal cases). In some
clinical trials, while drug administration is in standard
dosage, some patients had a high serum concentration
and the adverse drug reactions developed; other ones
had a low serum drug concentration, and as a result, the
treatment was ineffective [1].
In consideration of the foregoing, we will try to answer
three questions:
– Why the efficiency of pharmacotherapy is not more
than 60% in spite of the existence of concepts of
evidence-based medicine?
– Why the frequency of the adverse drug reactions is
increasing?* Correspondence: masik_8787@mail.ru
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distribution, and reproduction in any medium– Why when standard dosage of plenty of administered
drugs, the range of drug serum concentration is so wide?
The answers on these questions are in the cycle of
‘movement’ of drugs in the human's organism presented in
Figure 1. The key points of this cycle are as follows: an en-
zyme activity of biotransformation system (mainly the ac-
tivity of the isoenzymes of the cytochrome P-450) and drug
transporters that determine personal pharmacokinetics [2].
Nowadays, it is well known that [3]:
– 40% of drugs are metabolized with the involvement
of the isoenzymes of the cytochrome P-450 (CYP450)
– 8% of drugs are prodrugs, and their active ‘drugs’ are
active metabolites.
The examples of prodrugs and enzymes of biotransform-
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Figure 3 Frequency of ‘slow’ alleles of different isoenzymes of the cytochrome P-450 among the Moscovites.
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Figure 5 The principle of the activity of the isoenzymes of the
cytochrome P-450.
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cytochrome P-450in drug metabolism
Ninety percent of drugs are metabolized with the involve-
ment of five isoforms of the isoenzymes of the cytochrome
P-450 (CYP3A4, CYP2D6, CYP2C9, CYP1A2, CYP2C19)
(Figure 2).
The main factors that influence on the activity of the
isoenzymes of the cytochrome P-450 are as follows [4]:
– genetic polymorphism
– combined administered drugs (induction/inhibition)
– severity and character of the main and associated
conditions
– qualitative composition of food
The genetic polymorphism of the isoenzymes of the
cytochrome P-450 determines a personal activity of the
isoenzyme and sometimes a risk of the development of
the adverse drug reactions. We studied the frequency of
‘slow’ alleles of different isoenzymes of the cytochrome
P-450 among the Muscovites (more than 800 genotyping
tests were done). Eight to twenty percent of patients,
treated with drugs, substrates of isoenzymes of the cyto-
chrome P-450, had analytically determined the risk of
development of the adverse drug reactions (Figure 3) [5].
Such results of the genotyping tests let us conclude
that when the genetic polymorphism of the enzyme that
metabolizes the drug is more than 10% of the cases in
the population, the genotyping tests are necessary. But if
a drug is the prodrug, from which with the involvement
of the isoenzymes of the cytochrome P-450, an active
metabolite is formed, the genetic polymorphism may re-
sult not in the adverse drug reactions but in the ineffi-
ciency of the treatment.
An example is the anticancer drug, tamoxifen, from
which with the involvement of the CYP2D6, its activeFigure 4 The scheme of metabolite of tamoxifen to the active metabmetabolite, endoxifen, is formed. In women with breast
cancer, slow metabolizers of CYP2D6 (carrier state of slow
allele CYP2D6*4), endoxifen is formed in the lower levels,
and remission period is lower (Figure 4) [6].
Also, a patent example of the genetic polymorphism
influence on the development of the adverse drug reac-
tions is the phenomena of the development of Stevens–
Johnson syndrome during carbamazepine treatment
period in patients with carrier state of HLA-B*1502,
and the development of bleedings occurs during war-
farin (in standard doses) treatment period in patients
with carrier state of allele CYP2C9 [7].The isoenzymes of the cytochrome P-450 activity in the
range of personalized medicine
So, what should a physician do to make a pharmacother-
apy effective and safe? A physician should know how to
work in the range of personalized medicine. What is aolite, endoxifen.
Table 1 The activity of the isoenzymes of the cytochrome P-450 examination
The isoenzymes of the
cytochrome P-450
Drugs: the substrates of the isoenzymes The activity examination
CYP3A4 Slow channel-blocking agents, statins, H1-histamine
receptor blockers, cytostatics
• Cortisol/6-beta-hydroxycortisol concentration ratio in the urine [9]
• 5-Hydroxycholesterol concentration in the blood serum [10]
CYP2D6 Beta-blockers, antidepressants, antipsychotic drugs • Concentration of the pinoline and its metabolite, hydroxyl-1,2,3,
4-tetra-beta-hydrocarboline in the urine [11]
CYP2C9 Oral anticoagulant, NSAID, antidiabetic drugs • Concentration of losartan and its metabolite, E-3174 in the urine [12]
CYP2C19 Proton-pump inhibitors, clopidogrel, anticonvulsant
drugs
• Concentration of 6-hydroxyomeprazole and its metabolite in the
blood serum [13]
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Medicine Consortium (USA), personalized medicine is
the use of new methods of molecular analysis for the im-
provement of prognosis, prophylaxis and treatment of
the diseases. The personalized medicine should change
the development and realization of measures on prophy-
laxis and treatment of the diseases. According to experts,
the ‘instruments’ of the personalized medicine are gen-
omics, transcriptomics, proteomics and metabolomics
[8]. The study of the activity of the isoenzymes of the
cytochrome P-450 refers to metabolomics, and in spite of
the key role of cytochrome P-450 nowadays, there are no












Figure 6 Work layout of the center of personalized medicine.We offer a well-known principle for the isoenzymes of
the cytochrome P-450 activity tests: concentration ratio
of a substrate and its metabolite. If the concentration of
metabolite is more than 50%, the activity of the isoen-
zymes, involved into the metabolism, is concerned to be
high; if it is less than 30%, it is concerned to be low. The
scheme of this principle is presented on Figure 5.
Currently, we proved that the activity of the isoen-
zymes of the cytochrome P-450 is examined more safely
not with the help of exogenous but with the endogenous
substrates and their metabolites, for example: cortisone
(for CYP3A4), cholesterol (for CYP3A4), testosterone (for
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tography (HPLC) with mass spectroscopy detection. The
exogenous substrates for the activity of the isoenzymes of
the cytochrome P-450 examination are presented in the
Table 1: omeprazole (for CYP2C9), losartan (for CYP2C19),
caffeine (for CYP1A2), debrisoquine (for CYP2D6)
and midazolam (for CYP3A4). The metabolite tests are
established on the HPLC with UV detection.
Thus, we demonstrated that the concentration of the
drug in the blood serum depends on the activity of the
metabolism enzymes, particularly on the isoenzymes of
the cytochrome P-450. If we know the level of the activ-
ity of these isoenzymes, we can choose a proper drug
and its dosage to achieve a clinical effect and a low per-
centage of the adverse drug reactions.
Conclusions
Centers of personalized medicine: implementation
instruments of personalized medicine in clinical practice
To promote a methodology of the personalized medicine
and evaluation methods of the activity of the isoenzymes
of the cytochrome P-450 in clinical practice, federal and
regional centers of personalized medicine are necessary.
The workflow of the center of the personalized medicine
is presented on Figure 6.
For the workflow management skilled staff, laborator-
ies of pharmacokinetics and pharmacodynamics, know-
ledge in the area of personalized medicine among the
general practitioners and health professionals is needed.
There are stages of formation of such centers of
personalized medicine:
1. The formation of a contract with FSBI Scientific
Center of Assessment of Medical Products under
MHSD of Russian Federation, I.M. Sechenov First
Moscow State Medical University, P.A. Herzen
Moscow Research Oncological Institute.
2. The information (in the form of methodical
documents and lectures) about the drugs that are
metabolized with the involvement of the isoenzymes
of the cytochrome P-450 with the information about
reasons that can enhance and weaken the
isoenzymes activity should be given to the general
practitioners of MPI.
3. The development of the working scheme between
a general practitioner of the MPI and a
coordinator (consultant of the center). At first, a
general practitioner sends by e-mail case history
and specific questions for the consultant of the
center to answer, connected with pharmacotherapy
(the choice of drug and dosage regimen). The
consultant's work is compared with the duty in the
hospital and should be paid in accordance with
these principles.Personalized medicine is an innovative and science-intensive
instrument for the improvement of the effectiveness and
safety of pharmacotherapy of the socially significant
diseases
The Europe key staffs of clinical pharmacology continu-
ally made an emphasis on timelines of this direction for
the practical healthcare:
– The first president of the European Association for
Clinical Pharmacology and Therapeutics (EACPT),
emeritus professor of the Karolinska University
(Stockholm, Sweden) and a member of the Nobel
Committee for medicine, Folke Sjöqvist: ‘The
personalized medicine is a preferred direction in
Europe nowadays’.
– The ex-president of the European Association for
Clinical Pharmacology and Therapeutics (EACPT) and
the director of the Institute of Pharmacology (Kiel,
Germany), professor Ingolf Cascorbi: ‘The personalized
medicine is a rapidly developing discipline, aimed to
the objective scientific basis for the studying the
personal differences in drug reactions’.
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